Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?  

In nearly all cases, I would stop the TNF inhibitor (TNFi). Though there is no evidence that these drugs raise the risk for solid organ tumor, the clinician must tread cautiously. First, the patient may require other potentially immune-suppressive anti-cancer therapies (plus radiation in some cases)...